Literature DB >> 8852401

How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.

P Ragnhammar1, H Blomgren.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8852401     DOI： 10.1007/bf01571196

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  107 in total

1.  A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.

Authors:  N Petrelli; L Herrera; Y Rustum; P Burke; P Creaven; J Stulc; L J Emrich; A Mittelman
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

2.  Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma.

Authors:  S Wadler; P H Wiernik
Journal:  Semin Oncol       Date:  1990-02       Impact factor: 4.929

3.  The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.

Authors:  N Petrelli; H O Douglass; L Herrera; D Russell; D M Stablein; H W Bruckner; R J Mayer; R Schinella; M D Green; F M Muggia
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

4.  Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations.

Authors:  J L Grem; E Chu; D Boarman; F M Balis; R F Murphy; N McAtee; C J Allegra
Journal:  Semin Oncol       Date:  1992-04       Impact factor: 4.929

5.  Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC).

Authors:  F Di Costanzo; R Bartolucci; F Calabresi; M Sofra; M Marzola; V Belsanti; C Boni; M Bacchi
Journal:  Ann Oncol       Date:  1992-05       Impact factor: 32.976

6.  Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.

Authors:  J L Grem; E Jordan; M E Robson; R A Binder; J M Hamilton; S M Steinberg; S G Arbuck; R A Beveridge; A N Kales; J A Miller
Journal:  J Clin Oncol       Date:  1993-09       Impact factor: 44.544

7.  Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer.

Authors:  L L Danhauser; J H Freimann; T L Gilchrist; J U Gutterman; C Y Hunter; A C Yeomans; A B Markowitz
Journal:  J Clin Oncol       Date:  1993-04       Impact factor: 44.544

8.  Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells.

Authors:  S H Berger; C H Jenh; L F Johnson; F G Berger
Journal:  Mol Pharmacol       Date:  1985-11       Impact factor: 4.436

9.  Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study.

Authors:  C J Punt; J T Burghouts; J J Croles; P A van Liessum; P H de Mulder; Y Kamm
Journal:  Cancer       Date:  1993-10-01       Impact factor: 6.860

10.  Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism.

Authors:  E Cadman; R Heimer; L Davis
Journal:  Science       Date:  1979-09-14       Impact factor: 47.728
View more
  1 in total

1.  Synthesis and antitumor activity of amino acid ester derivatives containing 5-fluorouracil.

Authors:  Jing Xiong; Hai-Feng Zhu; Ya-Juan Zhao; Yun-Jun Lan; Ji-Wang Jiang; Jing-Jing Yang; Shu-Feng Zhang
Journal:  Molecules       Date:  2009-08-25       Impact factor: 4.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.